Levofloxacin and Bismuth-containing Therapy Versus Quadruple Therapy as Second-line Treatment of Resistant Helicobacter Pylori Infection

• Status: Completed
• Trial end date: 2013-04-01
• Target enrollment: 0
• Participant gender: All

Summary

To test the efficacy of 14 day levofloxacin and bismuth-containing second-line therapy for resistant Helicobacter pylori infection, to compare with the classical quadruple therapy.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shanghai Jiao Tong University School of Medicine
• Treatments: Amoxicillin; Bismuth; Bismuth subsalicylate; Levofloxacin; Metronidazole; Ofloxacin; Proton Pump Inhibitors; Tetracycline

Criteria

Inclusion Criteria:

• all patients had failed H.pylori therapies including clarithromycin, metronidazole and/or amoxicillin (if not allergic) before.

Exclusion Criteria:

• patients less than 18 years old,

• previous gastric surgery,

• pregnancy,

• lactation,

• major systemic diseases,

• administration of antibiotics,

• bismuth,

• antisecretory drugs in the preceding 8 weeks, or

• allergy to any one of the medication used in the quadruple regimens.